Assessing the therapeutic efficacy of Cefoperazone Sodium and Sulbactam Sodium in managing surgical site infections: a retrospective analysis
Abstract Surgical site infections (SSIs) pose significant challenges in surgical care, impacting patient recovery and healthcare costs. The increasing prevalence of antibiotic-resistant bacteria necessitates effective antimicrobial strategies. This study assesses the therapeutic efficacy and safety...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-77906-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Surgical site infections (SSIs) pose significant challenges in surgical care, impacting patient recovery and healthcare costs. The increasing prevalence of antibiotic-resistant bacteria necessitates effective antimicrobial strategies. This study assesses the therapeutic efficacy and safety of Cefoperazone Sodium and Sulbactam Sodium in managing SSIs and compares its effectiveness against a standard treatment. A retrospective analysis was conducted on 110 patients with clinically and microbiologically confirmed SSIs from December 2020 to December 2023. Patients were divided into two groups: 55 received Cefoperazone Sodium and Sulbactam Sodium, while 55 were treated with Cefuroxime. The efficacy was evaluated based on microbiological eradication and clinical improvement, assessed after 3 days of treatment. Statistical analyses were performed using SPSS version 27.0, with significance set at p < 0.05. Demographic and clinical characteristics showed no significant differences between groups, ensuring comparability. The observation group demonstrated a cure rate of 58.18% and an overall efficacy rate of 94.55%. In contrast, the control group showed a cure rate of 32.73% and an overall efficacy rate of 70.91%. Statistical analysis revealed a significant difference in therapeutic success between the groups (Chi-square value of 9.16, p-value < 0.05). The combination of Cefoperazone Sodium and Sulbactam Sodium could provide a more effective option for managing SSIs, potentially improving cure rates and overall treatment outcomes compared to Cefuroxime. |
|---|---|
| ISSN: | 2045-2322 |